anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To provide spherical particle of a polymer having amino group at side chain and modified by ionic adsorption with a compound having anionic group and useful for coloring, imparting of ultraviolet absorptivity, prevention of chapped skin, etc., as an additive for cosmetic, soap, shampoo, etc. CONSTITUTION:The objective spherical polymer particle has an average particle diameter of 0.1-100mum (preferably 0.2-70mum), contains amino group at side chain and modified by ionic adsorption with a compound having anionic group (e.g. sulfone group, carboxyl group, phenolic OH group, etc.) such as acidic dye, ultraviolet absorber, L-ascorbic acid, colorant for food, colorant for cosmetic, colorant for quasi-drug, etc. The polymer is chitosan or a copolymer containing acrylic monomer or aromatic vinyl monomer having amino group. A cosmetic having high bleed-out resistance can be produced by the use of the polymer particle. The particle exhibits a function of slow-releasing agent by contacting with an aqueous solution of NaCl, etc.
CYCLOSET is contraindicated in:

  * Patients with known hypersensitivity to bromocriptine, ergot-related drugs, or any of the excipients in CYCLOSET.
  * Patients with syncopal migraine. Bromocriptine increases the likelihood of a hypotensive episode among patients with syncopal migraine. Loss of consciousness during a migraine may reflect dopamine receptor hypersensitivity. CYCLOSET is a dopamine receptor agonist and may, therefore, potentiate the risk for syncope in these patients.
  * Postpartum patients. Serious and life-threatening adverse reactions have been reported with bromocriptine use in this population [see Warnings and Precautions (5.7), Adverse Reactions (6.2)] . 
  * Lactating patients. CYCLOSET contains bromocriptine which inhibits lactation [see Use in Specific Populations (8.2)] .
The novel antibiotic A-28086 complex containing the factors A, B and D is produced by culturing Streptomyces aureofaciens NRRL 5758 or Streptomyces aureofaciens NRRL 8092 in a culture medium, which contains assimilable sources for carbohydrate, nitrogen and inorganic salts, in submerged aerobic fermentation conditions until these organisms have produced a significant amount of antibiotic activity in the culture medium. The antibiotic is then separated off from the culture medium. The novel antibiotic can be dissociated into the factors A, B and D. These can be converted into the corresponding physiologically tolerated salts. The novel antibiotic can likewise be converted into C2-C6-acyl esters. The novel antibiotic A-28086 complex, the factors A, B and D, the physiologically tolerated salts thereof and also C2-C6-acyl esters thereof are used to increase the feed intake of ruminants. They can additionally be used for the prevention or treatment of coccidiosis in poultry.
[GB1512568A]
No exercise plus experimental MitoQ, 20mg/d. Each MitoQ capsule contains 20 mg of mitoquinol mesylate. Dosage: 20 mg orally per day for 10 weeks.
Probiotics were also shown to reduce severity of AEDS when administered to infants with early onset AEDS. In contrast, only a few studies have evaluated the therapeutic effectiveness of probiotics on the groups of older children with established AEDS. In these studies, administration of Lactobacillus strains to unselected children aged 1 year and over was associated with improvement in the clinical severity of eczema. The purpose of this study was to evaluate the clinical efficacy in AEDS of a newly identified probiotic strain, Lactobacillus sakei KCTC 10755BP, which showed the most potent inhibitory activity against S aureus growth among Lactobacillus species in our preliminary experiment. We administered L sakei to an unselected group of children aged 2 to 10 years with moderate and severe AEDS and evaluated the clinical outcome at the end of the intervention. In addition, we also measured levels of serum chemokines as activity markers for AEDS to provide a more objective evidence for the beneficial role of this probiotic.
The invention discloses an Escherichia coli bacterial strain for preparing an active short peptide. The strain is preserved as Escherichia coli, and is deposited with the China General Microbiological Culture Collection Center (CGMCC). The accession address is No.3 Yard No.1 Beichen West Road, Chaoyang District, Beijing. The accession date is October 24th, 2014. The accession number is CGMCCNo.9842. The Escherichia coli related in the invention is used for preparing an Escherichia coli bacterial preparation. According to the invention, the Escherichia coli bacterial strain for preparing an active short peptide is high in in-vivo activity and low in cost.
NEW MATERIAL:The compound of formula I [R<1> is H or 1-5C alkyl; R<2>-R<4> are H, 1-5C alkoxy or OH; two of R<2>-R<4> may together form the group of formula IV or formula V; m is 0-4; n is 1-4; dotted line is single bond or double bond] or its salt. EXAMPLE:The compound of formula VI. USE:A medicine. A cardiotonic agent. It is administered orally or parenterally at a dose of 0.1-10mg/kg body weight daily in the case of oral administration. PREPARATION:The compound of formula I can be produced e.g. by reacting a carboxylic acid of formula II with an alkyl halocarboxylate such as ethyl chloroformate in a mixed solvent consisting of N,N-dimethylformamide and tetrahydrofuran, etc., at -20-+100 deg.C for 5-10hr in the presence of a basic compound such as triethylamine and reacting the resultant mixed acid anhydride with an amine of formula III at -20-+100 deg.C for 5min-10hr.
Thirty-eight patients with confirmed nasal polyps (20 with primary CRSwNP and allergic rhinitis (AR) and 18 with CRSWNP) and 20 patients with chronic hypertrophic rhinitis were included. The nasal polyps and mucosal specimens of all patients were collected and analyzed by Western Blot.
A display system for a medical suite comprises a scanning device configured to capture scanning data in the medical suite. At least one display configured to display information in an operating region of the medical suite. A controller is in communication with the scanning device and the display. The controller is configured to control the scanning device to capture identifying information of a patient. Based on the identifying information, the controller is configured to authenticate an identity of the patient. Based on the identity, the controller is configured to access a patient record for the patient. The controller is further configured to control the at least one display to display information based on the patient record.
Patients undergoing hip replacement surgery will receive either fluid therapy with active comparator (Voluven) or placebo (Sodium Chloride. Patients will receive minimum 7,5 ml/kg in the first hour of the surgery and 5 ml/kg in the subsequent hours.
The present invention relates to a deodoring powder or preparation for tragomaschalia, which is used for removing the odor of human armpit sweat and has the advantages of convenient use and low cost. The deodoring powder for tragomaschalia is composed of acetylsalicylic acid powder, and the deodoring preparation for tragomaschalia is composed of the aqueous solution of acetylsalicylic acid. The deodoring powder for tragomaschalia contains the acetylsalicylic acid powder, and the deodoring preparation for tragomaschalia contains the aqueous solution of the acetylsalicylic acid. The present invention has the advantages of low cost, simple production method, simple use method and favorable effect. After the deodoring powder or preparation for tragomaschalia provided by the present invention is used for the deodorization of tragomaschalia, the present invention has no odor and can not influence the normal perspiration and the physiological function of patients. The present not only relieves the vexation of tragomaschalia patients, but also avoids the influence of the tragomaschalia patients to other people in public places and offices so as to achieve the purpose of purifying environments.
DIACOMIT can cause decreases in appetite and weight. In controlled studies in patients with Dravet syndrome, the incidence of decreased appetite was 46% in DIACOMIT-treated patients, compared to 10% in patients on placebo. The incidence of decreased weight was 27% in DIACOMIT-treated patients, compared to 6% in patients on placebo. Nausea and vomiting also occurred more frequently in DIACOMIT-treated patients [see Adverse Reactions (6.1)]. Given the frequency of these adverse reactions, the growth of pediatric patients treated with DIACOMIT should be carefully monitored. In some cases, decreasing the dose of concomitant valproate by 30% per week can reduce the decrease in appetite and weight.
BACKGROUND: Nowadays type 2 diabetes mellitus (T2DM) leads to population mortality growth. Today glucagon-like peptide type 1 receptor agonists (GLP-1 RA) are one of the most promising glucose-lowered drugs with anorexigenic and cardioprotective effects. The present study aims to determine the effects of GLP-1 RA semaglutide 6-month therapy on T2DM patient metabolic parameters and adipose progenitor cell health.
METHODS: T2DM patients (N = 8) underwent clinical characterization and subcutaneous fat biopsy at start point and after semaglutide 6-month therapy. Adipose-derived stem cells (ADSC) were isolated by enzymatic method. Cell proliferation analysis was performed by MTT and immunocytochemistry. White and beige adipogenesis was analyzed by BODIPY493/503 staining and confocal microscopy. Adipocyte's metabolic properties were estimated by 3H- and 14C-based metabolic assays. Thermogenesis analysis was performed by ERthermAC staining and confocal microscopy. Protein markers were assessed by Western blotting.
RESULTS: Semaglutide 6-month therapy demonstrated significant anorexigenic and glucose-lowering effects. However, insulin sensitivity (HOMA-IR and M-index) was unchanged after therapy. Semaglutide 6-month therapy increased ADSC proliferation and white and beige adipogenesis. Moreover, lipid droplets fragmentation was observed in beige adipocytes. Both white and beige adipocytes after semaglutide therapy demonstrated 2-3 fold growth of glucose uptake without changes in insulin sensitivity. Newly formed white adipocytes demonstrated glucose utilization for active ATP synthesis, whereas beige adipocytes for canonical thermogenesis.
CONCLUSIONS: Our study has revealed that semaglutide 6-month therapy has not only systemic anorexigenic effects, but can markedly improve adipose tissue health. We have demonstrated critical restoration of ADSC renewal functions, which potentially can be involved in semaglutide based weight loss.
PROBLEM TO BE SOLVED: To obtain a new compound excellent in effects on preventing the generation of various kinds of ulcers and useful as an antibacterial agent against Helicobacter pyroli, etc. SOLUTION: A compound of formula I  R1 , R2 are each a lower alkyl; W is a group of formula II [R3 is an alkenyl; R4 is a lower alkyl, a halogen, etc.; X is O, S, etc.; Y is C, N; (m) is 1-3; (n) is 0-2], etc.,}, e.g. a compound of formula III. The compound of formula I (W is a group of formula II) is obtained by converting a carboxylic acid of formula IV into an acid anhydride in the presence of an activating agent such as diphenylphosphinic chloride and subsequently reacting the acid anhydride with an amine of formula V. The reaction is carried out in the presence of an organic base such as triethylamine as an additive in a solvent such as an aromatic hydrocarbon, e.g. benzene, or an ether compound, e.g. tetrahydrofuran, at a reaction temperature of usually -15 deg.C to the refluxing temperature of the solvent by a mixed acid anhydride method.
The development of glucagon-like peptide 1 receptor agonists (GLP-1RA) for type 2 diabetes and obesity was followed by data establishing the cardiorenal benefits of GLP-1RA in select patient populations. In ongoing trials investigators are interrogating the efficacy of these agents for new indications, including metabolic liver disease, peripheral artery disease, Parkinson disease, and Alzheimer disease. The success of GLP-1-based medicines has spurred the development of new molecular entities and combinations with unique pharmacokinetic and pharmacodynamic profiles, exemplified by tirzepatide, a GIP-GLP-1 receptor coagonist. Simultaneously, investigational molecules such as maritide block the GIP and activate the GLP-1 receptor, whereas retatrutide and survodutide enable simultaneous activation of the glucagon and GLP-1 receptors. Here I highlight evidence establishing the efficacy of GLP-1-based medicines, while discussing data that inform safety, focusing on muscle strength, bone density and fractures, exercise capacity, gastrointestinal motility, retained gastric contents and anesthesia, pancreatic and biliary tract disorders, and the risk of cancer. Rapid progress in development of highly efficacious GLP-1 medicines, and anticipated differentiation of newer agents in subsets of metabolic disorders, will provide greater opportunities for use of personalized medicine approaches to improve the health of people living with cardiometabolic disorders.
Personalised nutritional advice: daily dietary programme with specific meals, products, recipes, food portions (in grams) based on the Meditteranean diet together with physical activity guidelines, all generated by a food database clinical decision support system (CDSS). Scheduled phone interviews every 15 days with the appointed dieticians assisted nutritional and lifestyle consultation.
Participants with Parkinson disease receive the sham Medx Console System and the sham Vielight 810 intranasal stand alone unit, since the devices deliver no near infrared light. These sham interventions occur during 16 lab sessions (1.5 hours each) during an 12 week period, plus daily 25 minute 'at home' intranasal stimulation interventions, 4 days each week.
Cangrelor may be used as a bridge when temporary interruption of dual antiplatelet therapy is necessary. However, the optimal dose and monitoring of cangrelor in patients remains unknown, especially in the setting of mechanical circulatory support (MCS). We conducted an observational, single-center, retrospective cohort study of patients who had percutaneous coronary intervention within 3 months and received cangrelor while admitted to any intensive care unit. The primary outcome was the incidence of any major adverse cardiovascular event. Secondary outcomes included VerifyNow platelet reactivity units (PRUs) measured while on cangrelor and any bleeding events while on cangrelor. A total of 92 patients were included. The most common reason for cangrelor use was in the periprocedural setting, with or without MCS (42%-45%), followed by NPO status (26%-28%) and MCS alone (22%-24%). The primary outcome of major adverse cardiovascular event occurred in 1 patient (1.1%). Of 92 patients, 77% had a P2Y12 level collected within 24 hours, and 89% of the cohort was able to achieve the goal P2Y12 PRU of <194. The median P2Y12 value within 24 hours of cangrelor initation was 115 PRU (40-168 PRU). We observed a bleed event rate of 23% (21/92). We found a standardized protocol of cangrelor dosing in critically ill patients who received a drug-eluting stent in the past 3 months to be successful in achieving a goal P2Y12 PRU. Although the optimal PRU remains unknown, cardiovascular clinicians may monitor these levels to help guide decisions regarding cangrelor management. Future randomized controlled trials should evaluate the optimal PRU threshold to balance risks of ischemia and bleeding.
Severe, potentially life-threatening and fatal skin reactions have been reported. In clinical trials, these include cases of Stevens-Johnson syndrome, toxic epidermal necrolysis and erythema multiforme. Hypersensitivity reactions including Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) have also been reported and were characterized by rash, constitutional findings, and sometimes organ dysfunction, including hepatic failure. In Phase 3 clinical trials, Grade 3 and 4 rashes were reported in 1.3% of subjects receiving etravirine compared to 0.2% of placebo subjects. A total of 2.2% of HIV-1-infected subjects receiving etravirine discontinued from Phase 3 trials due to rash [see Adverse Reactions (6.1)]. Rash occurred most commonly during the first 6 weeks of therapy. The incidence of rash was higher in females [see Adverse Reactions (6.1)]. Stevens-Johnson syndrome was reported in 1.1% (2/177) of pediatric patients less than 18 years of age receiving etravirine in combination with other HIV-1 antiretroviral agents in an observational study.

Discontinue etravirine immediately if signs or symptoms of severe skin reactions or hypersensitivity reactions develop (including, but not limited to, severe rash or rash accompanied by fever, general malaise, fatigue, muscle or joint aches, blisters, oral lesions, conjunctivitis, facial edema, hepatitis, eosinophilia, angioedema). Clinical status including liver transaminases should be monitored and appropriate therapy initiated. Delay in stopping etravirine treatment after the onset of severe rash may result in a life-threatening reaction.
All subjects will receive both Active (Carbon Dioxide Drug Delivery System) and Placebo. This is a single-blind study so subjects will not know the order. Subjects will receive 3 doses of active and 3 doses of placebo. One dose is a 60 second delivery of CO2 or placebo. At the discretion of the investigator, subjects may receive up to 3 additional doses of CO2.
AIMS: This study is designed to identify risk factors of postoperative nausea and vomiting (PONV) in patients after gynecologic laparoscopic surgery and establish a nomogram model.
METHODS: In this retrospective and multicenter study, we collected and analyzed data from 1233 patients who underwent gynecologic laparoscopic surgery. The Lasso algorithm was used to optimize the selection of independent variables in the development group. Multivariate logistic regression analysis was used to explore the risk factors of PONV to develop the predictive nomogram model. Finally, we used an internal and external verification group and machine learning (ML) to evaluate the accuracy and clinical applicability of the model.
RESULTS: The dosage of sufentanil in patient-controlled intravenous analgesia (PCIA), the dosage of remifentanil, the use of neostigmine, duration of surgery and the maximum value of the PETCO2 were risk factors of PONV in patients after gynecologic laparoscopic surgery. In contrast, the dosage of propofol during the surgery and the use of steroids were protective factors. The nomogram was then established to predict the incidence of PONV in these patients based on the above eight indicators. The C-index of the development group, internal, and external verification groups are 0.802, 0.857, and 0.966, respectively.
CONCLUSION: A nomogram model was developed to predict the incidence of PONV in patients after gynecologic laparoscopic surgery. This model was found to be reliable and of high clinical value.
Verapamil is a calcium ion influx inhibitor (L-type calcium channel blocker or calcium channel antagonist). Verapamil exerts its pharmacologic effects by selectively inhibiting the transmembrane influx of ionic calcium into arterial smooth muscle as well as in conductile and contractile myocardial cells without altering serum calcium concentrations. Verapamil binding is voltage-dependent with affinity increasing as the vascular smooth muscle membrane potential is reduced. In addition, verapamil binding is frequency dependent and apparent affinity increases with increased frequency of depolarizing stimulus.

The L-type calcium channel is an oligomeric structure consisting of five putative subunits designated alpha-1, alpha-2, beta, tau, and epsilon. Biochemical evidence points to separate binding sites for 1,4-dihydropyridines, phenylalkylamines, and the benzothiazepines (all located on the alpha-1 subunit). Although they share a similar mechanism of action, calcium channel blockers represent three heterogeneous categories of drugs with differing vascular-cardiac selectivity ratios.
Symptoms include vomiting, numbness, tingling, pain and cyanosis of the extremities associated with diminished or absent peripheral pulses; hypertension or hypotension; drowsiness, stupor, coma, convulsions and shock. A case has been reported of reversible bilateral papillitis with ring scotomata in a patient who received five times the recommended daily adult dose over a period of 14 days. Treatment consists of removal of the offending drug. Maintenance of adequate pulmonary ventilation, correction of hypotension, and control of convulsions and blood pressure are important considerations. Treatment of peripheral vasospasm should consist of warmth, but not heat, and protection of the ischemic limbs. Vasodilators may be beneficial but caution must be exercised to avoid aggravating an already existent hypotension.
Moxifloxacin 0.5%/Dexamethasone 0.1% ophthalmic solution, 1 drop instilled in the study eye 2 days before surgery, followed by 1 drop instilled 4 times a day the day before surgery. On the day of surgery, 1 drop was instilled 60 minutes prior to the procedure.
Cohort F2 will involve an expansion to evaluate atezolizumab administered in combination with daratumumab and the MTD of pomalidomide determined in Cohort F1 in participants with relapsed or refractory MM who have received 4 or more lines of prior treatment and are refractory to the last line of treatment. NOTE: This cohort is randomized.
PURPOSE:An aqueous solution containing a fat-soluble vitamin active substance or a ubiquinone useful as an injection, having improved stability, obtained by blending the aqueous solution with hydrogenated lecithin and a neutral amino acid, adjusting the blend to a specific pH. CONSTITUTION:A fat-soluble vitamin active substance such as fat-soluble vitamin A, E, K active substance, etc., or a ubiquinone such as preferably ubidecarenone, and hydrogenated lecithin are added to a small amount of water, pressurized or treated with ultrasonic wave, etc. under heating preferably at 60-70 deg.C, so that they are uniformly dispersed into water coarsely, a neutral amino acid such as glycine, alanine, etc. is added to the dispersion, which is adjusted to 5.5-8pH. The dispersion is blended with other components such as a germicide, an isotonizing agent, etc. and the rest of water, and dispersed uniformly, to give the desired aqueous solution. An amount of the hydrogenated lecithin is 0.1-15pts.wt. based on 1pt.wt. fat-soluble vitamin active substance or ubiquinone, and an amount of the neutral amino acid is preferably 0.05-6wt./vol% based on the aqueous solution.